Moreover, miR920 acts on several cancer pathways, involving genes of great potential in oncology, such as CEBPB, MYC and TGFBR2, which are related to the proliferation, anti-apoptosis, invasion, and metastasis pathways in pathologies such as colorectal cancer, leukemia, lymphoma, sarcoma, prostate cancer, and neuroblastoma [23]. Here, MYC is linked to leukemia.